Melphalan in Multiple Myeloma
For transplant-eligible patients, high-dose melphalan 200 mg/m² is the standard conditioning regimen before autologous stem cell transplantation (ASCT), while transplant-ineligible patients should avoid melphalan-containing regimens in favor of novel agent combinations that preserve stem cell reserve and deliver superior survival. 1, 2
Transplant-Eligible Patients: High-Dose Melphalan Conditioning
Standard Dosing
Melphalan 200 mg/m² is the Category 1 recommended conditioning regimen for ASCT in multiple myeloma. 3, 4 This represents the standard of care based on extensive clinical trial data demonstrating optimal efficacy without superiority of alternative conditioning regimens (melphalan plus total body irradiation or melphalan with other chemotherapy agents). 4
The European Myeloma Network guidelines confirm that biological rather than chronological age should guide eligibility decisions, with full-dose melphalan 200 mg/m² appropriate for patients aged 65-70 years who have Karnofsky performance status >90% and HCT-CI = 0 or R-MCI 0-3. 1
Dose Reduction Criteria
Melphalan dose reductions to 100-140 mg/m² should be considered in specific clinical scenarios: 1
Performance status: Karnofsky <90% warrants dose reduction, unless poor performance is directly attributable to myeloma itself (bone disease, vertebral fractures, anemia) rather than comorbidities—in which case full-dose melphalan may restore performance through disease control. 1
Comorbidity burden: HCT-CI >1 or R-MCI 4-6 requires dose reduction. 1
Organ dysfunction requiring dose reduction includes: 1
- Cardiac: LVEF 40-50% or NYHA class II
- Hepatic: bilirubin >1.5× ULN or AST/ALT >2.5× ULN
- Pulmonary: DLCO or FEV1 40-80%
- Renal: GFR <60 mL/min
Critical Renal Considerations
For renal dysfunction (creatinine >150 µmol/L or >1.7 mg/dL), transplant cannot be recommended as standard therapy until renal function improves with initial myeloma treatment. 3 The evidence for transplant benefit is limited to patients with creatinine <150 µmol/L after hydration and remission-inducing chemotherapy. 3
When renal impairment is directly caused by myeloma, the risk-benefit calculation may favor full-dose melphalan 200 mg/m² to achieve optimal disease control. 1 However, recent data show significantly higher grade 3-4 mucositis in CKD patients (P = 0.013), though engraftment, PFS, and OS remain comparable. 5
A 50% dose reduction is required if BUN ≥30 mg/dL, which reduced severe leukopenia from 50% to 11% and drug-related mortality from 10% to 3% in clinical trials. 6
Comparative Efficacy Data: 200 mg/m² vs 140 mg/m²
Disease status at transplant determines optimal melphalan dose: Patients transplanted in less than partial response achieve significantly better outcomes with melphalan 200 mg/m² (adjusted HR for OS: 0.5, PFS: 0.54, relapse: 0.56). 7 Conversely, patients in very good partial response or complete response may benefit from melphalan 140 mg/m² (adjusted HR for OS: 2.02). 7
Age, renal function, prior proteasome inhibitor exposure, gender, and Karnofsky score do not interact with survival or relapse rates when comparing melphalan doses. 7 High-risk versus standard-risk cytogenetics show no significant survival differences between 200 mg/m² and 140 mg/m². 7
Recent 2023-2025 data confirm that melphalan 140 mg/m² achieves equivalent minimal residual disease (MRD) negativity rates at 10⁻⁵ and 10⁻⁶ sensitivity (64% vs 60%, P = 0.7) compared to 200 mg/m², with comparable PFS and OS despite older age and higher comorbidity burden in the reduced-dose cohort. 8
Transplant-Ineligible Patients: Avoid Melphalan-Based Regimens
Critical Pitfall to Avoid
Do not use melphalan-containing regimens in transplant-eligible patients before stem cell collection, as extensive alkylator exposure compromises stem cell yield and eliminates future transplant options. 3, 4, 2 High-dose glucocorticoid-based regimens (e.g., bortezomib/lenalidomide/dexamethasone) are preferable for induction. 3
Preferred Regimens for Non-Transplant Candidates
Daratumumab + lenalidomide + dexamethasone (Dara-Rd) continuously until progression is the Category 1 preferred regimen for standard-risk disease, achieving 30-month PFS of 70.6% versus 55.6% with Rd alone. 2
Lenalidomide + low-dose dexamethasone continuously is a Category 1 option, delivering 2-year OS of ~91% and superior outcomes to melphalan-based regimens. 2
For high-risk disease or renal insufficiency, bortezomib + lenalidomide + dexamethasone (VRd) provides median PFS of 41 months versus 29 months with Rd alone. 2
When Melphalan-Based Regimens Are Acceptable
Daratumumab + bortezomib + melphalan + prednisone (Dara-VMP) is a Category 1 regimen for transplant-ineligible patients, achieving 72% PFS at 18 months versus 50% for VMP alone. 9, 2 However, melphalan-containing regimens are rarely used in North America due to leukemogenic risk and myelosuppression. 10, 9
Modified VMP schedules using once-weekly bortezomib (instead of twice-weekly) reduce peripheral neuropathy (32.1% vs 46.8%, P <0.0001) while maintaining equivalent median PFS (19.6 vs 20.7 months). 11
Evolving Practice Patterns
- Reduced use of melphalan as frontline therapy reflects the need for long-term treatment strategies. 10 With prolonged OS in myeloma, early melphalan exposure creates leukemogenic risk and myelosuppression that limit future treatment options. 10 Several effective alternatives with reduced toxicity are now available. 10
Salvage and Repeat Transplantation
A second ASCT at relapse should be considered if remission duration after first ASCT was ≥18 months (Grade 1B recommendation); this cutoff extends to 24 months in the context of novel induction/maintenance. 1 Second ASCT should be offered as first salvage therapy rather than after multiple failed lines. 1
Salvage ASCT is safe and beneficial particularly when remission duration exceeds 18-24 months, though PFS from second ASCT (12-18 months) is shorter than after first ASCT. 4
FDA-Approved Indication
- Melphalan hydrochloride for injection is FDA-approved for palliative treatment of multiple myeloma patients for whom oral therapy is not appropriate. 6